Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > More coverage in China

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on Sep 07, 2021 10:31am

128 Views

Post# 33818594

RE:RE:RE:RE:RE:More coverage in China

It will really help TH's stock price if PDC become the next "big thing" in drug research and if their phasw 1a results are impressive. TH could be seen as the leader in this new area if that is how it plays out and that would defintely help the share price a lot. Let's hope everything falls nicely into place in the months ahead.

scarlet1967 wrote: It seems like there are more coverage of the targeted drug delivery now, all these frequent articles are new, never came across them before!

Recently, another biomedical company called Theratechnologies also announced the research progress of two PDCs in its R&D pipeline. Up to now, two PDC products have been approved worldwide, and a number of PDC products have entered the clinical stage. At present, this field has attracted international pharmaceutical giants including Novartis, AstraZeneca, Roche, etc. to deploy one after another. Domestic innovative drug companies such as Sheng Nuoji Pharmaceutical and Mainstream Biology have also begun to conduct PDC research and development.

Based on its versatility and advantages, PDC is a research field with broad development prospects. As more innovative biomedical companies join, PDC drugs are expected to achieve rapid development.

https://m.jrj.com.cn/madapter/stock/2021/09/07085333396635.shtml